Lee et al., 2009 - Google Patents
Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in AfricaLee et al., 2009
- Document ID
- 10568755031754932699
- Author
- Lee C
- Kuo W
- Beri S
- Kapre S
- Joshi J
- Bouveret N
- LaForce F
- Frasch C
- Publication year
- Publication venue
- Vaccine
External Links
Snippet
Periodic epidemics of group A meningococcal (Mn A) meningitis continue to occur in sub- Saharan Africa. For its prevention, a Mn A polysaccharide (PS)–tetanus toxoid (TT) conjugate vaccine was developed using reductive amination of polysaccharide aldehydes …
- 229960005486 vaccines 0 title abstract description 57
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48238—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid
- A61K47/48246—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent
- A61K47/4833—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lee et al. | Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa | |
Seeberger | Discovery of semi-and fully-synthetic carbohydrate vaccines against bacterial infections using a medicinal chemistry approach: focus review | |
CA2223080C (en) | Antigenic group b streptococcus type ii and type iii polysaccharide fragments having a 2,5-anhydro-d-mannose terminal structure and conjugate vaccine thereof | |
CA2142981C (en) | Vaccines against group c neisseria meningitidis | |
US9057716B2 (en) | Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines | |
WO2000033882A1 (en) | A vi-repa conjugate vaccine for immunization against salmonella typhi | |
Gao et al. | Immunoactivity of protein conjugates of carba analogues from Neisseria meningitidis a capsular polysaccharide | |
US20150182613A1 (en) | Meningococcal And Pneumococcal Conjugate Vaccine And Method Of Using Same | |
Chang et al. | Relevance of O-acetyl and phosphoglycerol groups for the antigenicity of Streptococcus pneumoniae serotype 18C capsular polysaccharide | |
Humpierre et al. | Expanding the scope of Ugi multicomponent bioconjugation to produce pneumococcal multivalent glycoconjugates as vaccine candidates | |
Hennessey Jr et al. | Lessons learned and future challenges in the design and manufacture of glycoconjugate vaccines | |
Pawlowski et al. | Preparation of pneumococcal capsular polysaccharide-protein conjugate vaccines utilizing new fragmentation and conjugation technologies | |
Guttormsen et al. | Rational chemical design of the carbohydrate in a glycoconjugate vaccine enhances IgM-to-IgG switching | |
US8202520B2 (en) | Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine | |
US5738855A (en) | Synthesis of typhoid fever vaccine from a plant or fruit polysaccharide | |
Gudlavalleti et al. | Comparison of Neisseria meningitidis serogroup W135 polysaccharide–tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non-O-acetylated and chemically de-O-acetylated polysaccharide | |
Yu et al. | The Pneumococcal Polysaccharide‐Tetanus Toxin Native C‐Fragment Conjugate Vaccine: The Carrier Effect and Immunogenicity | |
Cuello et al. | New meningococcal C polysaccharide-tetanus toxoid conjugate: Physico-chemical and immunological characterization | |
AU767047B2 (en) | Vaccines against (escherichia coli) O157 infection | |
US7527797B1 (en) | Vibrio cholerae 0139 conjugate vaccines | |
Liao et al. | Characterization of a human monoclonal immunoglobulin M (IgM) antibody (IgMBEN) specific for Vi capsular polysaccharide of Salmonella typhi | |
Hosseini et al. | Evaluation of PRP anti body Haemophilus influenza type b (Hib) response with carrier protein by ELISA |